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INTRODUCTION
Historically, the 2007 World Health Organization (WHO) 
classification of central nervous system (CNS) tumours clas-
sified anaplastic astrocytoma, anaplastic oligodendroglioma, 
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Background    There was no practical guideline for the management of patients with central nervous 
system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisci-
plinary academic society, developed the guideline for glioblastoma successfully and published it in 
Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO 
guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established.
Methods    The Working Group was composed of 35 multidisciplinary medical experts in Korea. 
References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL 
databases using specific and sensitive keywords as well as combinations of keywords. Scope of the 
disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults. 
Results    Whenever radiological feature suggests high grade glioma, maximal safe resection if 
feasible is globally recommended. After molecular and histological examinations, patients with ana-
plastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard 
brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocy-
toma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for 
glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and ana-
plastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoad-
juvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy.
Conclusion    The KSNO’s guideline recommends that WHO grade III cerebral glioma of adults 
should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy 
according to molecular and histological features of tumors.
Key Words  Korean Society for Neuro Oncology; Guideline; Grade III Gliomas; Practice.
anaplastic oligoastrocytoma, anaplastic ependymoma, and 
anaplastic pleomorphic xanthoastrocytoma as grade III glio-
mas. Actually, WHO grade III gliomas are not common as 
glioblastomas. All other malignant gliomas including WHO 
grade II and III gliomas are composed of 10.2% of all prima-
ry CNS tumors in the United State [1] and 5.3% in Korea [2]. 
Such classification was based on morphological features on 
light microscopy of hematoxylin and eosin-stained sections, 
immunohistochemical expression of lineage associated pro-
teins, and ultrastructural characterization [3]. However, stud-
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ies over the past two decades have clarified the genetic basis 
of tumorigenesis for some brain tumor entities, raising the 
possibility that such an understanding may contribute to 
new classification of these tumors [4]. The use of integrated 
phenotypic and genotypic parameters for classification of gli-
omas adds a level of objectivity that has been missing from 
some aspects of the diagnostic process in the past [5]. Ac-
cording to the new WHO classification of CNS tumours pub-
lished in 2016, the following gliomas are classified as WHO 
grade III gliomas: 1) anaplastic astrocytoma, isocitrate dehy-
drogenase (IDH)-mutant, 2) anaplastic oligodendroglioma, 
IDH-mutant and 1p19q-codeleted, 3) anaplastic pleomorphic 
xanthoastrocytoma, 4) ependymoma, v-rel avian reticuloen-
dotheliosis viral oncogene homolog A (RELA) fusion-positive, 
and 5) anaplastic ependymoma [4].
In terms of genotypic characteristics, mutation status of 
IDH1/2 and codeletion of 1p19q are more important to diag-
nose WHO grade III gliomas than methylation status of the 
O6-methyl guanine DNA methyltransferase (MGMT) gene 
promoter. Several WHO grade III gliomas in recent classifi-
cation have morphological characteristics of those in previ-
ous pathological classification. If they do not have IDH-mu-
tation, they have a behavior of WHO grade IV gliomas. 
Therefore, although these gliomas are not categorized as 
grade III, they should be treated with the same protocol for 
WHO grade IV gliomas [4].
Despite WHO grade III gliomas have better outcome and 
longer survival than WHO grade IV gliomas, results of treat-
ment are still very disappointing. There are certain obstacles 
to overcome these tumors because of frequent recurrence, 
common progression to higher grade gliomas, and refracto-
riness to conventional therapies, etc. [6]. Therefore, many 
clinical trials have been performed and many are also ongo-
ing to overcome these serious diseases. Although there are 
no new therapeutic modalities such as those for WHO grade 
IV gliomas, combinations of conventional cytotoxic chemo-
therapy agents and other agents such as target therapy and/
or immunotherapy have been developed [7-9]. To apply re-
cently established combinations or newly developed agents 
for patients with grade III gliomas, comprehensive and ad-
vanced cancer networks or academic societies for CNS tu-
mors of western countries such as the National Comprehen-
sive Cancer Network (NCCN) [10-12] and the European 
Association for Neuro-Oncology (EANO) [13] are updating 
their guidelines for CNS tumor regularly. Besides clinical 
characteristics such as age of patients, adjuvant temozolo-
mide, and methylation status of MGMT gene promoter as 
prognostic factors for patients with WHO grade III gliomas 
[7,8], genetic background such as IDH mutation and codele-
tion of 1p19q are also important to estimate the prognosis of 
patients with WHO grade III gliomas [6].
However, it is a critical point that circumferences of treating 
patients with WHO grade III gliomas in Korea are much dif-
ferent from those in other countries. The incidence of WHO 
grade III gliomas is relatively lower [2] and clinical practice is 
much limited in Korea because Korean government supports 
medical care financially by the National Health Insurance 
System which limits application of updated therapeutic mo-
dalities to patients.
Although the clinical practical guideline for WHO grade 
IV gliomas has been just developed and published recently by 
the Korean Society for Neuro-Oncology (KSNO), a multidis-
ciplinary academic society for CNS tumors [14], the actual 
guideline for the management of patients with other CNS tu-
mors in Korea is not available yet. The KSNO established a 
Working Group for developing practice guideline for CNS tu-
mor in February 2018. Recently it is developing a guideline 
for CNS tumor based on updated information. The objective 
of KSNO guideline is to provide physicians with evidence-
based recommendations and consensus expert opinion for 
managing patients with glioblastomas in daily clinical prac-
tice. It will also serve as a source of knowledge for institutions 
and insurance companies involved in cancer care in Korea.
KSNO GUIDELINE WORKING GROUP
A Working Group was appointed by the KSNO in Febru-
ary 2018 to establish guidelines on the management of glio-
blastoma patients. These guidelines should be optimized 
considering the unique medical circumstance in Korea. The 
KSNO Guideline Working Group was composed of 35 medi-
cal experts in Korea, including 18 neurosurgeons, 8 radiation 
oncologists, 1 medical oncologist, 2 neuroradiologists, 3 pe-
diatric oncologists, 2 pathologists, and 1 neurologist. As 
there is no medical specialty for neuro-oncology in Korea, 
neurosurgeons (especially brain tumor surgeons) usually 
play the role of neuro-oncologists in clinical practice.
References were identified by searching PubMed, MED-
LINE, EMBASE, and Cochrane CENTRAL databases using 
specific and sensitive keywords as well as combinations of 
keywords. Scope of the disease was confined to cerebral ana-
plastic astrocytoma and anaplastic oligodendroglioma in 
adults aged ≥18 years because other WHO grade III gliomas 
are relatively uncommon in Korea. Therefore, WHO grade III 
glioma in the spinal cord, anaplastic ependymoma, or ana-
plastic pleomorphic xanthoastrocytoma in the brain was not 
included. Abstracts presented at the official year-end confer-
ence of KSNO in December 2018 were considered relevant. 
When available, we also collected existing guidelines from 
national multidisciplinary neuro-oncological societies such as 
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insufficient to suggest a high-grade glioma even with contrast 
enhancement. Therefore, magnetic resonance image (MRI) 
with contrast enhancement is essential to diagnose a high-
grade glioma. In order to obtain sufficient tissue for histo-
pathological diagnosis, neurosurgical intervention is manda-
tory even if it is for stereotactic biopsy. To achieve maximal 
safe resection, neuronavigation system, intraoperative CT or 
MRI, intraoperative ultrasonography, intraoperative mapping 
technique, and fluorescence-guidance with 5-aminolevuliniv 
acid are recommended. Histopathological diagnosis should 
be officially based on 2016 WHO Classification of Tumors of 
the Central Nervous System [4]. Codeletion of 1p19q testing 
and IDH1/IDH2 mutation test are essential parts of molecular 
diagnosis for grade III gliomas. Also, MGMT promoter 
methylation test is required for workup of WHO grade III gli-
omas. If the histopathological diagnosis is WHO grade IV 
gliomas, patients should be treated based on guideline for 
WHO grade IV gliomas instead of this guideline [14].
ADJUVANT TREATMENT OF 
WHO GRADE III GLIOMAS
Anaplastic astrocytoma, IDH-mutant
In terms of histopathological and molecular features, the 
following modalities should be considered for patients with 
anaplastic astrocytoma, IDH-mutant (Fig. 2): standard brain 
radiotherapy and adjuvant temozolomide chemotherapy, or 
standard brain radiotherapy with concurrent and adjuvant te-
mozolomide chemotherapy, or standard brain radiotherapy 
with neoadjuvant or adjuvant PCV (procarbazine+lomustine
+vincristine) combination chemotherapy, or standard brain 
the NCCN and EANO. The final reference list was generated 
based on originality and relevance to the scope of this guide-
line. The strategy of establishing this guideline was mainly 
based on NCCN and EANO guidelines with modifications 
and changes according to the unique background of Korea. 
Scientific evidence was assessed and graded according to 
the following categories: high level evidence (evaluated from 
multiple populations and derived from randomized clinical 
trials or meta-analysis or systemic review) and low level evi-
dence (evaluated from limited population and derived from 
non-randomized studies, including observational studies, 
cohort studies, and case-control studies).
To establish recommendation levels, the following criteria 
were used. Level I (strong recommendation) required a high 
level of evidence and uniform consensus among panels. Level 
II (weak recommendation) required a high level of evidence 
but not uniform consensus among panels or a low level of evi-
dence but uniform consensus among panels. Level III (indi-
vidual decision) required a low level of evidence but not uni-
form consensus among panels. Level IV (not recommendable) 
required contents being not beneficial or harmful. Recom-
mendations with level I or level II evidence were not marked. 
However, those with level III and level IV evidence were 
marked at the end of each recommendation in this guideline.
DIAGNOSIS OF WHO GRADE III 
GLIOMAS
When radiological feature suggests a high-grade glioma, 
multidisciplinary approach for treatment planning should be 
considered if feasible (Fig. 1). Computed tomography (CT) is 
Fig. 1. Guideline for diagnosis of WHO grade III gliomas. To diagnose WHO grade III gliomas, MRI with gadolinium enhancement is essen-
tial. A multidisciplinary approach for treatment planning is recommended if feasible. Primarily, WHO grade III gliomas should be diagnosed 
histopathologically for tissues obtained by neurosurgical intervention. KSNO, Korean Society for Neuro-Oncology; MRI, magnetic reso-
nance image; WHO, World Health Organization.
KSNO Guidelines version 2019.01
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radiotherapy alone (Level III). Adjuvant temozolomide is rec-
ommended at 150–200 mg/m2 for five consequential days ev-
ery 4 weeks. The number of cycles of adjuvant temozolomide 
chemotherapy can be up to 12 (Level III). During concurrent 
chemoradiotherapy with temozolomide, the dose of temo-
zolomide is recommended at 75 mg/m2. Additional temo-
zolomide after concurrent chemoradiotherapy is recom-
mended at 150–200 mg/m2 for five consequential days every 
4 weeks for adjuvant purpose. The number of cycles of adju-
vant temozolomide chemotherapy is also up to 12. The maxi-
mum number of cycles of adjuvant chemotherapy using PCV 
regimen is 6. Despite low evidence, panels have consensus 
(although not uniform) that standard brain radiotherapy 
without adjuvant chemotherapy should be considered for 
WHO grade III glioma patients with poor performance status 
[Karnofsky Performance Scale (KPS) ≤60] (Level III).
Anaplastic astrocytoma, NOS, and anaplastic 
astrocytoma, IDH-wild type
As most anaplastic astrocytomas (except genetic feature of 
IDH-mutant) usually have similar clinical and pathological 
behaviors, patients should be treated based on the guideline 
for grade IV gliomas (Fig. 2).
Anaplastic oligodendroglioma 
According to the 2016 WHO classification of tumors of the 
CNS, prior diagnoses of oligoastrocytoma and anaplastic oli-
goastrocytoma are newly designated as NOS categories since 
these diagnoses should be rendered only in the absence of di-
agnostic molecular testing or in the very rare instance of a 
dual genotype oligoastrocytoma [4]. Therefore, the following 
treatment should be considered for anaplastic oligodendro-
gliomas including those with IDH-mutant and 1p19q-codele-
tion and those without result of molecular testing: standard 
brain radiotherapy and neoadjuvant or adjuvant PCV combi-
nation chemotherapy, or standard brain radiotherapy with 
concurrent and adjuvant temozolomide chemotherapy, or 
standard brain radiotherapy alone (Level III) (Fig. 3). The 
maximum number of cycles of the adjuvant chemotherapy 
using PCV regimen is 6. During concurrent chemoradiother-
apy with temozolomide, the dose of temozolomide is recom-
mended at 75 mg/m2. Additional temozolomide after concur-
rent chemoradiotherapy is recommended at 150–200 mg/m2 
for five consequential days every 4 weeks for adjuvant pur-
pose. The number of cycles of the adjuvant temozolomide 
chemotherapy is also up to 12. Despite low evidence, the pan-
els have consensus (although not uniform) that standard 
brain radiotherapy without adjuvant chemotherapy for WHO 
grade III glioma should be considered for patients with poor 
performance status (KPS ≤60) (Level III).
Follow up radiological study
Radiological follow-up using MRI with gadolinium en-
hancement is recommended. For patients with anaplastic as-
trocytoma, regular check-up at 2–6 weeks after radiotherapy, 
then every 2–4 months for 3 years, then every 6–12 months is 
Fig. 2. Guideline for adjuvant therapy of patients with anaplastic astrocytoma, IDH-mutant, NOS, and IDH-wildtype. 1) For the patients with 
anaplastic astrocytoma, IDH-mutant, standard brain radiotherapy and adjuvant temozolomide chemotherapy, or standard brain radiotherapy 
with concurrent and adjuvant temozolomide chemotherapy, or standard brain radiotherapy with neoadjuvant or adjuvant PCV chemothera-
py, or standard brain radiotherapy alone are recommended. 2) For the patients with anaplastic astrocytoma, NOS, and IDH-wildtype, the 
practical protocol for glioblastoma patients is recommended. IDH, isocitrate dehydrogenase; KSNO, Korean Society for Neuro-Oncology; 
PCV, procarbazine+lomustine+vincristine; MRI, magnetic resonance image.
KSNO Guidelines version 2019.01
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recommended (Fig. 2). For patients with anaplastic oligoden-
drogliomas, regular check-up 2–6 weeks after radiotherapy, 
then every 3–6 months for 3 years, then every 12 months (Fig. 
3) is recommended regardless of age or therapeutic option. In 
spite of the absence of definite evidence for interval of follow-
up imaging study, there is a uniform consensus among the 
panels for the above schedule for follow-up radiologic study.
MRI at this time can be much informative to detect radia-
tion-induced brain swelling and pseudoprogression after ra-
diotherapy. The physician can care patients more comfort-
ably based on appropriate imaging study.
TREATMENT OF RECURRENT WHO 
GRDE III GLIOMAS
Diagnosis of WHO grade III glioma’s recurrence can be in-
distinguishable from pseudoprogression on MRI within the 
first 3 months after completion of radiotherapy. However, the 
following radiologic findings can suggest recurrence as rec-
ommended by radiologic assessment of neurooncology 
(RANO) criteria [15]: 1) 25% or more increase in enhancing 
lesions despite stable or increasing steroid dose, 2) significant 
increase of the lesion in fluid-attenuated inversion recovery 
(FLAIR) image and T2 weighted image not attributable to 
other non-tumor causes, and 3) any new lesion. Also, if clini-
cal deterioration (not attributable to other non-tumor causes 
or steroid decrease) occurs simultaneously, true progression is 
strongly suggested. If recurrence is suspected in conventional 
MRI, it is better to consider the following options: 1) under-
going biopsy, 2) checking functional radiologic study such as 
MR spectroscopy, MR perfusion, brain positron emission to-
mography (PET)-CT, or 3) checking MRI again and compar-
ing changes that may be due to progression versus radiation 
necrosis. When recurrence of the tumor is suggested clinically 
and radiologically, surgical resection is always recommended, 
if feasible. Even in case of recurrence of WHO grade III glio-
mas with difficulty for complete resection such as diffuse, 
multi-focal, or deep located lesion, surgical treatment can be 
considered to reduce mass effect, improve neurological symp-
toms, and define progression into WHO grade IV gliomas. 
After confirm recurrence, the following salvage treatment 
should be considered: systemic chemotherapy and/or reirra-
diation and/or clinical trials and/or supportive treatment if 
patient has poor performance status (Fig. 4).
The following adjuvant systemic therapies can be considered 
for recurrent WHO grade III gliomas based on physician’s de-
cision: cytotoxic chemotherapy, target therapy, and/or immu-
notherapy, etc. However, the efficacy of standard-of-care treat-
ment such as adjuvant temozolomide chemotherapy for 
recurrent WHO grade III glioma is suboptimal for salvage 
purpose. Thus, for eligible patients, consideration of clinical 
trials is highly encouraged.
PRINCIPLES OF MANAGEMENT FOR 
WHO GRADE III GLIOMAS
Brain imaging
Many imaging modalities are available and used in neu-
rooncology primarily to make treatment decisions in Korea. 
Imaging is always recommended to investigate emergent signs 
or symptoms. MRI of the brain (with and without contrast) is 
the gold standard modality to investigate brain tumors. It pro-
vides a static picture of brain tumors. It has a benefit in that it 
provides a reasonably good delineation of tumors. In MRI, 
high grade tumors and brain leptomeningeal metastases usu-
ally show enhancement while low-grade tumors usually do 
Fig. 3. Guideline for adjuvant therapy of patients with anaplastic oligodendroglioma. The patients should be treated with following modali-
ties; 1) standard brain radiotherapy and neoadjuvant or adjuvant PCV chemotherapy, or 2) standard brain radiotherapy with concurrent and 
adjuvant temozolomide chemotherapy, or 3) standard brain radiotherapy alone. KSNO, Korean Society for Neuro-Oncology; PCV, procarba
zine+lomustine+vincristine; MRI, magnetic resonance image.
KSNO Guidelines version 2019.01
WHO GRADE III GLIOMAS (2): ADJUVANT THERAPY (2)
MOLECULAR AND HISTOLOGIC FEATURES ADJUVANT TREATMENT
•Standard brain radiotherapy and neoadjuvant
  or adjuvant PCV chemotherapy
  or
•Standard brain radiotherapy with concurrent 
  and adjuvant temozolomide chemotherapy
  or
•Standard brain radiotherapy alone11 (Level III)
FOLLOW UP
Brain MRI
2–6 weeks after
radiotherapy, 
then 
every 3–6 months
for 3 years,
then 
every 12 months
Anaplastic oligodendroglioma 
(IDH-mutant, 1p19q codeletion)
Anaplastic oligodendroglioma, NOS
68  Brain Tumor Res Treat  2019;7(2):63-73
KSNO’s Guideline for WHO Grade III Gliomas
not. However, MRI has a limitation in that it is sensitive to 
movement. In addition, metallic objects can cause artifacts. 
Thus, patients with implantable devices cannot receive an 
MRI. Moreover, claustrophobia or renal insufficiency may be 
an issue. Postoperative brain MRI should be performed within 
24–72 hours after surgery for gliomas and other tumors to de-
termine the extent of resection.
CT scan of the brain (with and without contrast) is usually 
considered for patients who cannot undergo an MRI. CT has a 
benefit of avoiding claustrophobia or implanted devices in the 
body. It is faster than an MRI. However, CT has a limitation in 
that it lacks resolution, especially for tumor located within the 
posterior fossa and for patients with renal insufficiency.
MR spectroscopy can be used to assess metabolites within 
tumor and normal tissues. It may be useful for differentiating 
tumors from radiation necrosis. It may also be helpful for 
grading tumors or assessing therapeutic response. The area 
showing the most abnormal features would be the best place 
to target for a biopsy. However, it has limitation for tumors 
near vessels, air space, or bone. 
MR perfusion can be used to measure cerebral blood vol-
ume in tumors. It may be useful for differentiating the grade of 
tumor or tumor versus radiation necrosis. The area with the 
highest perfusion would be the best place for a biopsy. Howev-
er, it has also limitation for tumors near vessels, air space, or 
bone, and small-volume lesions. 
PET-CT using fluorodeoxyglucose (FDG) has a limitation 
for functional diagnosis of WHO grade III glioma due to high 
uptake of FDG in the brain with normal biologic metabolism. 
However, PET-CT using methionine, an essential amino acid, 
may be helpful for differentiating the tumor progression ver-
sus radiation necrosis. This technology is not commonly used 
in the clinical field in Korea. Further development of applica-
tion is necessary for casual use in clinical practice.
Multidisciplinary care
During treatment, most patients with WHO grade III glio-
mas will be managed by various subspecialists. Close and reg-
ular communication among all providers across multi-disci-
plines is essential. Utilization of a brain tumor board or 
multidisciplinary clinic care models can facilitate interactions 
among various subspecialists, ideally including allied health 
services (e.g., physical, occupational and speech therapies, 
nursing, psychology, and social services) to optimize treat-
ment plan recommendations. 
As treatment proceeds, it is important that the patient and 
his/her family understand the role of each team member. 
One attending physician who mainly cares for the patient 
should be determined as early as possible and the attending 
physician should contact patients regularly for follow up. Ad-
ditionally, the attending physician can facilitate referral to 
appropriate specialist.
The patient is strongly encouraged to participate in various 
clinical trials. Practitioners should discuss any local, regional, 
and national options for which the patient may be eligible 
and advantages/disadvantages of participation. The center 
that treats neuro-oncology patients should encourage pa-
tients to participate in large collaborative trials in order to 
have another option for patients.
Throughout treatment, patient’s health-related quality of 
Fig.4. Guideline for recurrent WHO grade III gliomas. Surgical resection is always recommended if feasible. After surgical resection, the fol-
lowing therapeutic options are considered: 1) systemic chemotherapy, and/or 2) reirradiation, and/or 3) enrollment of clinical trials and/or 4) 
supportive treatment if poor performance status. KSNO, Korean Society for Neuro-Oncology.
KSNO Guidelines version 2019.01
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life should remain the highest priority and guide clinical deci-
sion-making. While therapeutic response on radiologic study 
can be a good indicator of successful therapy, other non-ra-
diologic indicators of therapeutic response such as overall 
well-being, cognitive function, physical and motor function-
ing in day-to-day activities, communication ability, social 
functioning and family interactions, nutrition, pain control, 
long-term consequences of treatment, and psychological is-
sues should also be considered.
Patients should be informed of the possibility of pseudo-
progression, its approximate incidence, and potential investi-
gations that may be needed if pseudoprogression is suspected. 
Close follow-up imaging, MR spectroscopy, PET-CT imag-
ing, and repeat neurosurgical intervention including biopsy 
and surgical resection may be necessary if clinically indicated. 
Brain tumor surgery
General principles of surgical resection of WHO grade III 
glioma of brain are as follows: gross total resection when ap-
propriate, minimal surgical morbidity, and accurate diagno-
sis. The following factors should be considered when deciding 
surgical resection: age, performance status, feasibility of de-
creasing the mass effect with surgery, resectability, including 
number of lesions, location of lesions, time since last surgery 
in recurrent patients, and new versus recurrent tumor [12]. 
Suspected pathology should also be considered with the fol-
lowing points: benign versus malignant, possibility of other 
non-cancer diagnoses, and projected natural history. For pa-
tients with IDH1 mutants, there is evidence suggesting that a 
supra-marginal resection is the most appropriate, which 
would include not only enhancing areas, but also T2/FLAIR 
areas when appropriate in terms of safe surgical approach 
with the use of any and all surgical adjuncts possible [16].
Options of surgical resection include gross total resection 
where feasible, stereotactic biopsy, and open biopsy/debulk-
ing followed by planned observation or adjuvant therapy. In 
order to obtain the maximal safe resection, neuronavigation 
systems, intraoperative MRI or CT, intraoperative ultraso-
nography, fluorescence-guided with 5-aminolevulinic acid, 
and intraoperative mapping techniques may be helpful. 
For histopathological diagnosis and genetic information, 
sufficient tissue should be sent to the pathologist for neuro-
pathology evaluation and molecular correlates analysis. Fro-
zen section analysis when possible can help with intraopera-
tive decision making. The tissue should be reviewed by an 
experienced neuropathologist.
Postoperative brain MRI should be performed within 24–
72 hours after surgery for WHO grade III  glioma to deter-
mine the extent of resection. The extent of resection should 
be judged based on postoperative imaging study. It should be 
used as a baseline to assess further therapeutic efficacy or tu-
mor progression.
Pathology examination
Incorporation of relevant diagnostic markers, including 
histopathologic and molecular information described in the 
2016 WHO Classification of Tumors of the Central Nervous 
System, should be considered as standard practice for tumor 
classification. Molecular/genetic characterization comple-
ments standard histologic analysis. It provides additional di-
agnostic and prognostic information that can greatly im-
prove diagnostic accuracy, influence treatment selection, and 
possibly improve management decision-making.
For standard histopathologic examination of WHO grade 
III glioma of brain, basic histologic examination is per-
formed based on the description in the WHO Classification 
of Tumors of the Central Nervous System [4]. Interobserver 
discrepancies in histologic diagnosis and grading are recog-
nized issues due to the inherently subjective nature of certain 
aspects of histopathologic interpretation (e.g., astrocytic vs. 
oligodendroglial morphology). In addition, surgical sam-
pling does not always capture all relevant diagnostic features 
of morphologically heterogeneous tumors.
Through genetic and molecular testing, WHO grade III gli-
omas can be differentiated more accurately in terms of prog-
nosis and, in some instances, response to different therapies. 
However, molecular/genetic characterization does not replace 
standard histologic assessment. It serves as a complementary 
approach to provide additional diagnostic and prognostic in-
formation that often enhances treatment selection. Although 
there are no identified targeted agents with demonstrated effi-
cacy in WHO grade III glioma, the panel encourages molecu-
lar testing of tumors such as next generation sequencing be-
cause if a driver mutation is detected, it may be reasonable to 
treat patient with a targeted therapy on a compassionate use 
basis, and/or the patient may have more treatment options in 
the context of a clinical trial.
Molecular testing also has a valuable role in improving diag-
nostic accuracy and prognostic stratification that may inform 
treatment selection. For example, codeletion of 1p19q testing 
is an essential part of molecular diagnostics for oligodendro-
gliomas. Therefore, 1p19q codeletion testing should be consid-
ered to differentiate astrocytoma from oligodendrogliomas. 
Also, IDH1/IDH2 mutation testing is required for differential 
diagnosis between IDH-mutant and IDH-wildtype tumors. 
Additionally, MGMT promoter methylation is an essential 
part of molecular diagnostics for all high-grade gliomas.
Radiotherapy
Optimal timing of radiotherapy after surgical resection is 
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not established in WHO grade III glioma of brain. Delay in 
radiotherapy has not been shown to decrease survival. How-
ever, we recommend radiotherapy to be initiated at postop-
erative 2–6 weeks after full recovery from surgical interven-
tions. Whenever radiotherapy is planned for patients with 
WHO grade III gliomas, pre- and post-operative MRIs 
should be performed to define all target volumes, including 
gross and clinical tumor volume (GTV and CTV). Addition-
al MRI at the time of radiotherapy simulation can be used to 
account for changes in surgical cavity or lesions. CT-based 
3-dimensional calculation of dose distribution should be 
performed at any circumstance. 
The GTV should encompass preoperative tumor bed and 
enhancing lesions on T1-weighted image of postoperative 
MRI. The preoperative tumor bed should not be directly de-
lineated on the registered preoperative MRI on the planning 
CT in patients undergoing surgical resection. T2/FLAIR sig-
nals can also be included in the GTV if needed. Historical 
trials and international groups [e.g., Radiation Therapy On-
cology Group (RTOG) and European Organization for Re-
search and Treatment of Cancer (EORTC)] generally recom-
mend an expansion of 2–2.5 cm for CTV delineation to 
account for subclinical tumor infiltration. However, smaller 
CTV-margins may be reasonable based on retrospective 
studies (as low as 0.5 cm). Simple expansion from the GTV 
should be avoided. CTV should always be modified based on 
anatomical barriers for tumor infiltrations. A margin of 3–5 
mm from the CTV is usually recommended to create the 
planning target volume to account for errors from image-
registration and daily set-up of patients. However, the mar-
gin can also be reduced if daily image-guidance is performed. 
A total dose of 59.4–61.2 Gy is recommended as standard 
radiotherapy using a daily fraction of 1.8–2.0 Gy. A reduced 
field can be used after delivering 45–50.4 Gy. However, field 
reduction does not always need to be performed sequentially. 
When intensity-modulated radiotherapy (IMRT or IMPT) is 
used to avoid critical organs, simultaneous integrated boost 
techniques can be used. For fragile patients with old age or 
poor performance requiring hypofractionated radiotherapy 
in 1–4 weeks, the following dose-fractionation regimens are 
frequently adopted: 40.05 Gy/15 fractions, 34 Gy/10 frac-
tions, 50 Gy/20 fractions, and 25 Gy/5 fractions. No single 
scheme has been proven to be superior to another. Different 
schedules can also be used based on physician’s decision. The 
optimal margin for CTV expansion has not been established 
yet. Therefore, we recommend physicians to follow the prin-
ciples of standard radiotherapy. Absolute cumulative dose 
limits or optimal intervals between radiotherapy sessions are 
not established for these gliomas yet. Thus, delivery, dose, 
fraction, target volume, and techniques for reirradiation 
should be decided by a brain tumor radiation oncologist and 
through a multidisciplinary discussion whenever feasible.
DISCUSSION
This is the second practical guideline for CNS tumors de-
veloped by KSNO Guideline Working Group. Major differ-
ence of KSNO guideline between WHO grade IV and III gli-
oma is the way to classify patients. The first step of the 
guideline approaching patients with WHO grade IV gliomas 
was based on basic clinical features such as age and perfor-
mance status of patients. On the contrary, the first step of the 
guideline approaching those with WHO grade III gliomas 
was based on histological and molecular features of tumors. 
The reason is that molecular characteristics such as the status 
of IDH1/2 mutation and codeletion of 1p19q are the more 
important ones for predicting therapeutic outcome of WHO 
grade III glioma patients than clinical characteristics. The 
best prognosis was found in patients with IDH1/2 mutant 
and 1p19q codeleted tumors [6].
While histological definition of WHO grade IV glioma is 
relatively uncontentious among neuropathologists, histologi-
cally defined groups of anaplastic astrocytoma, anaplastic oli-
godendroglioma, and anaplastic oligoastrocytoma remain a 
major challenge for various reasons: 1) there is poor interob-
server agreement when diagnoses and grading are made by 
histological criteria alone [17], particularly concerning the 
classification of oligoastrocytomas [18], 2) their clinical 
courses  are highly variable, and 3) clinical management for 
them remains poorly standardized [19]. Therefore, in the 
2016 WHO classification of CNS tumors, prior diagnoses of 
oligoastrocytoma and anaplastic oligoastrocytoma are now 
designed as NOS categories since these diagnoses should be 
rendered only in the absence of diagnostic molecular testing 
or in the very rare instance of a dual genotype oligoastrocy-
toma [4].
As mentioned above, almost all medical practices are un-
der regulation by the National Health Insurance System in 
Korea. Limited therapeutic modalities are included in this 
guideline because the national system does not cover various 
therapeutic modalities such as temozolomide alone chemo-
therapy for newly diagnosed WHO grade III glioma even if 
patients have poor performance status, thus limiting clinical 
practice in the field of neuro-oncology in Korea. The Korean 
government permits only two therapeutic options such as 
standard brain radiotherapy and/or adjuvant nitrourea-based 
cytotoxic chemotherapy regardless of molecular features in-
cluding status of IDH1/2 mutation and 1p19q codeletion. 
Therefore, this guideline basically divided gliomas according 
to critical molecular and histological features instead of clini-
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cal status. Although the Korean National Health Insurance 
System does not permit concurrent chemoradiotherapy us-
ing temozolomide for newly diagnosed WHO grade III glio-
mas, the panels have a uniform consensus that this therapeu-
tic option can be considered for patients with such situation. 
Despite this guideline emphasizes the importance of molec-
ular and genetic diagnosis for the categorization of patients, 
only three tests were included in this guideline: IDH1/2 muta-
tion, 1p19q codeletion, and methylation status of MGMT gene 
promoter. As mentioned in this guideline, IDH1/2 mutation 
test is an essential part of molecular diagnostics for WHO 
grade III glioma because this mutation can distinguish lower-
grade glioma from primary glioblastoma [20,21]. IDH muta-
tions are commonly associated with MGMT gene promoter 
methylation [22], relatively favorable prognosis [23], and sur-
vival benefit for patients treated with radiation or alkylating 
chemotherapy [24]. Wild-type IDH1/IDH2 is associated with 
increased risk of aggressive disease [22], which makes anaplas-
tic astrocytoma, IDH-wildtype follow the guideline for WHO 
grade IV gliomas in this guideline. In fact, this molecular test-
ing is reliably screened by mutation-specific immunohisto-
chemistry without any practical difficulties in Korea. In the 
same manner, 1p19q deletion test is an essential part of molec-
ular diagnostics for WHO grade III glioma, especially oligo-
dendrogliomas. This codeletion confers a favorable prognosis. 
It is predictive of response to alkylating chemotherapy and 
combination therapy with radiation and alkylating chemo-
therapy [25,26]. Codeletion of 1p and 19q is generally detected 
by fluorescence in situ hybridization or polymerase chain reac-
tion in regular practice in Korea. Although the NCCN [12] 
and EANO guideline [13] recommend more tests for genetic 
alteration of grade III gliomas, including ATP-dependent X-
linked helicase (ATRX) gene mutation, telomerase reverse 
transcriptase (TERT) promoter mutation, and H3F3A muta-
tion, these more complex and detailed molecular tests were 
not included in this guideline due to practical limitations of 
individual institute in Korea. 
Fortunately, the Korean National Health Insurance System 
allows recurrent WHO grade III glioma to be treated by temo-
zolomide as well as lomustine and PCV combination regimen. 
However, bevacizumab which is permitted for patients with 
recurrent grade IV glioma is still limited for those with recur-
rent grade III glioma. Other recommended regimens in 
NCCN guideline [12] such as bevacizumab combined with 
chemotherapeutic agents (lomustine, temozolomide, and car-
boplatin, etc.) are also unavailable in Korea. Fortunately, recent 
data from CeTeG/NOA-09 randomized, open-label, phase 3 
clinical trial have suggested that lomustine-temozolomide 
combination chemotherapy might improve survival compared 
to temozolomide standard therapy in patients with newly di-
agnosed glioblastoma and methylated MGMT gene promoter 
[27]. Although this result was obtained not for WHO grade III 
glioma patients, but for glioblastoma patients, lomustine 
which is more commonly used in Korea can be considered for 
these patients after validation by further studies.
At recurrence, there is no standard or effective treatment for 
WHO grade III glioma in Korea or western countries. In fact, 
a recent randomized controlled phase 2 EORTC trial (TAVA-
REC) using combination chemotherapy of bevacizumab and 
temozolomide for recurrent WHO grade II and III gliomas 
without 1p19q codeletion failed to show improved overall sur-
vival [7]. For recurrent glioblastomas, a multicenter, open la-
bel, randomized, controlled, phase 2 trial (REGOMA) has 
shown survival benefit of regorafenib which is a target agent 
for vascular endothelial growth factor (VEGF)-independent 
angiogenesis [28]. This drug can be expected to be a new po-
tential treatment for patients with glioblastoma as well as 
WHO grade III gliomas after investigation in an adequately 
powered phase 3 study. Therefore, much less regimens can be 
used for patients, including several alkylating agents in Korea, 
than those in other countries. Due to a smaller number of pa-
tients in Korea, global pharmaceutical companies are reluctant 
to enroll Korean patients into their clinical trials for new drugs 
such as immunotherapeutic agents. Therefore, chances to par-
ticipate in clinical trials in Korea are very small. This back-
ground results in clinical trials to be recommended only at the 
time of recurrence in this guideline as in KSNO guideline for 
glioblastoma patients.
The weakness of this KSNO guideline for WHO grade III 
cerebral gliomas is not different from that of KSNO guideline 
for glioblastoma. The major weakness of this guideline is lim-
ited application to Korean patients with WHO grade III glio-
mas due to the unique medical atmosphere of Korea. There-
fore, it is less helpful for physicians treating patients outside of 
Korea. In order to use this guideline globally, Asian countries 
including Japan and China should have a comprehensive net-
work for brain tumor management that can cooperate and 
share their guidelines. Further, it will be helpful for Asian 
countries to establish a global guideline that is commonly ap-
plicable to these countries. The next hurdle to be overcome is 
molecular and genetic test for WHO grade III gliomas and 
whole brain tumors. Genetic information is now rapidly 
changing, making it difficult to establish definite guideline for 
clinical practice. The Consortium to Inform Molecular and 
Practical Approaches to CNS Tumor Taxonomy (cIMPACT-
NOW) is the notable example that shows rapid change in 
molecular diagnosis of brain tumors [29,30]. Recently, exome 
sequencing of anaplastic astrocytomas has suggested a dis-
tinct mutation profile from primary glioblastomas, including 
frequent mutations in Notch pathway genes [31]. In addition, 
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this guideline does not include medical management. In clini-
cal practice, physicians are still struggling to manage the mass 
effect, brain edema, radiation necrosis, seizures, endocrine 
dysfunctions, fatigues, psychological disorders such as de-
pression and anxiety, and venous thromboembolism [12]. 
However, the consensus for steroid therapy, the use of antiepi-
leptic drugs, and antipsychotic drugs for these patients is not 
satisfactory. Finally, this guideline did not include all WHO 
grade III cerebral gliomas. Only patients with anaplastic as-
trocytoma and anaplastic oligodendroglioma were subjects 
for this guideline. Other WHO grade III gliomas such as ana-
plastic ependymoma or anaplastic pleomorphic xanthoastro-
cytoma were not included in this guideline. Gliomas of the 
spinal cord were not subjects of this guideline either. There-
fore, the KSNO’s Guideline Working Group has plans to con-
tinue the process of updating guidelines so that the weakness 
of this version can be improved.
CONCLUSIONS
As there was no practical guideline for the management of 
brain tumor patients, the KSNO developed this guideline 
that should be applicable for physicians under unique medi-
cal circumstances in Korea. The KSNO Guideline Working 
Group composed of 35 multidisciplinary medical experts in 
Korea prepared “The KSNO guideline for WHO grade III 
cerebral glioma in adult: version 2019.01” as the second 
guideline following the KSNO Guideline for Glioblastoma. 
In summary, WHO grade III cerebral gliomas in the adults 
should be treated by maximal safe resection if feasible fol-
lowed by radiotherapy and/or chemotherapy according to 
individual molecular and histopathological features of tu-
mors. As data emerging in the past few years have led to sig-
nificant changes in the diagnosis, categorization, and treat-
ment of WHO grade III gliomas, we plan to update this 
guideline consistently. Also, consecutive guideline for other 
brain tumors such as WHO grade II gliomas, brain metasta-
sis, and meningiomas will be published by the KSNO Guide-
line Working Group.
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